Related Experiment Videos
Mutagenicity studies of muroctasin
Arzneimittel-Forschung
|July 1, 1988
Summary
The synthetic muramyl dipeptide derivative, N2-[(N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine (MDP-Lys(L18)), demonstrated no mutagenic potential. Tests including the Ames assay, in vitro cytogenetics, and micronucleus test confirmed its safety profile.
Area of Science:
- Immunology and Toxicology
- Drug Safety and Mutagenesis Studies
Background:
- Synthetic muramyl dipeptide derivatives are investigated for therapeutic potential.
- Assessing the mutagenicity of novel compounds like MDP-Lys(L18) is crucial for safety.
Purpose of the Study:
- To evaluate the mutagenic potential of N2-[(N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine (MDP-Lys(L18)).
- To determine if MDP-Lys(L18) poses a risk for genetic mutations.
Main Methods:
- Ames reverse mutation assay using S. typhimurium and E. coli strains.
- In vitro cytogenetic analysis of Chinese hamster cells.
- In vivo mouse micronucleus test following subcutaneous administration.
Main Results:
- MDP-Lys(L18) showed no mutagenic activity in bacterial reverse mutation assays.
- No chromosomal aberrations were observed in Chinese hamster cells treated with MDP-Lys(L18).
- The mouse micronucleus test revealed no increase in micronucleated erythrocytes.
Conclusions:
- MDP-Lys(L18) exhibits no demonstrable mutagenic potential.
- The compound is considered safe regarding genotoxicity based on the conducted assays.